A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Chronic Lymphocytic Leukemia Clinical Trial

Official title:

A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01460134
• Other study ID #: CDX1127-01
• Status: Completed
• Phase: Phase 1
• First received: October 12, 2011
• Last updated: January 29, 2018
• Start date: October 2011
• Est. completion date: October 16, 2017

Study information

• Verified date: August 2017
• Source: Celldex Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a study of CDX-1127, a therapy that targets the immune system and may act to promote anti-cancer effects. The study enrolls patients with hematologic cancers (certain leukemias and lymphomas), as well as patients with select types of solid tumors.

Description:

CDX-1127 is a fully human monoclonal antibody that binds to a molecule called CD27 found on certain immune cells and also on certain hematologic tumor cells and may act to promote anti-tumor effects.

This study will evaluate the safety and activity of escalating doses of CDX-1127 in patients with B-cell and T-cell hematologic malignancies known to express CD27 and solid tumors that are more likely to be responsive to the immune system.

Eligible patients who enroll in the dose escalation portion of the study will be assigned to one of 5 dose levels of CDX-1127. This first phase of the study will test the safety profile of CDX-1127 and will assess which dose to test in future studies.

During the Expansion phase, cohorts of approximately 15 patients each will receive the study treatment to continue to evaluate the safety profile of CDX-1127 and to determine if it has an effect on their cancer. Expansion cohorts may be limited to one or more tumor types.

Patients enrolled in the study may receive study treatment for up to 5 cycles, until their disease has progressed or until it is necessary to stop the treatment for safety or other reasons.

All patients enrolled in the study will be closely monitored to determine if their cancer is responding to treatment and for any side effects that may occur.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: October 16, 2017
• Est. primary completion date: December 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Among other criteria, patients must meet the following conditions to be eligible for the study:

1. 18 years of age or older.

2. Body Weight = 120 kg.

3. Histologic diagnosis of either a B-cell or T-cell hematologic malignancy known to express CD27 or one of the following solid tumors: metastatic melanoma, renal (clear) cell carcinoma, hormone-refractory prostate adenocarcinoma, ovarian cancer, colorectal adenocarcinoma or non-small cell lung cancer. For the solid tumor expansion cohorts, enrollment is limited to the following solid tumors: melanoma and renal cell carcinoma.

4. Tumor must be recurrent or treatment refractory with no remaining alternative, approved therapy options, with the following exception: melanoma patients enrolled in the expansion phase must have previously received ipilimumab and, for patients with the BRAF V600E mutation, vemurafenib, or have been offered such therapies and refused, and patients must have progressive disease subsequent to previous therapies.

5. Measurable or evaluable disease.

6. Have adequate blood, bone marrow, liver and kidney function as determined by laboratory tests.

7. If of childbearing potential (male or female), agree to practice an effective form of contraception during study treatment.

8. Have little or no side effects remaining from prior cancer therapies.

9. Provide written informed consent.

Exclusion Criteria:

Among other criteria, patients who meet the following conditions are NOT eligible for the study:

1. Known prior primary or metastatic brain or meningeal tumors.

2. Receiving treatment with immunosuppressive agents, including any systemic steroids.

3. Active infection requiring systemic therapy, known HIV infection, or positive test for hepatitis B surface antigen or hepatitis C.

4. Is being treated for anti-coagulation (i.e. warfarin) for reasons other than catheter patency.

5. Women who are pregnant or lactating.

6. Prior allogeneic bone marrow transplant.

7. Autologous bone marrow transplant within 100 days of first dosing.

8. Recent chemotherapy or other anti-cancer therapy (within 2 - 14 weeks depending on treatment type).

9. Systemic radiation therapy within 4 weeks or prior focal radiotherapy within 2 weeks prior to first dosing.

Related Conditions & MeSH terms

• Adenocarcinoma
• Any T-cell Malignancy
• Burkett's Lymphoma
• Carcinoma, Non-Small-Cell Lung
• CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma
• Chronic Lymphocytic Leukemia
• Colorectal Adenocarcinoma, Non-small Cell Lung Cancer)
• Hodgkin Disease
• Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid
• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, B-Cell, Marginal Zone
• Lymphoma, Mantle-Cell
• Mantle Cell Lymphoma
• Marginal Zone B Cell Lymphoma)
• Melanoma
• Neoplasms
• Ovarian Neoplasms
• Primary Lymphoma of the Central Nervous System
• Prostatic Neoplasms
• Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma

Intervention

Drug:
• CDX-1127
Patients will initially receive a single dose of CDX-1127, followed by a 28-day observation period and a Multi-Dose Phase (one "cycle" of 4 weekly doses of CDX-1127). All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional "cycles"). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression. The dose of CDX-1127 given for the Dose Escalation phase will depend on the cohort each patient is assigned to, and will range between 0.1 and 10.0 mg/kg of CDX-1127.
• CDX-1127
Patients will receive 4 weekly doses of CDX-1127 followed by an observation period. All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional "cycles"). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.
• CDX-1127
Patients will receive four doses of CDX-1127 administered every three weeks followed by an observation period. All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional "cycles"). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.

Locations

Country	Name	City	State
United States	University of Virginia Health System	Charlottesville	Virginia
United States	The Ohio State University Comprehensive Cancer Center	Columbus	Ohio
United States	Mary Crowley Cancer Research Centers - Medical City	Dallas	Texas
United States	Sarah Cannon Research Institute	Nashville	Tennessee
United States	Icahn School of Medicine at Mount Sinai Hess Center for Science and Medicine	New York	New York
United States	University of Pennsylvania Abramson Cancer Center	Philadelphia	Pennsylvania
United States	Oregon Health and Science University	Portland	Oregon
United States	Mayo Clinic	Rochester	Minnesota
United States	Mayo Clinic Arizona - Cancer Clinical Research Unit	Scottsdale	Arizona
United States	Stanford Cancer Center - Stanford University	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
Celldex Therapeutics

Country where clinical trial is conducted

United States, 

References & Publications (1)

Burris HA, Infante JR, Ansell SM, Nemunaitis JJ, Weiss GR, Villalobos VM, Sikic BI, Taylor MH, Northfelt DW, Carson WE 3rd, Hawthorne TR, Davis TA, Yellin MJ, Keler T, Bullock T. Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors. J Clin Oncol. 2017 Jun 20;35(18):2028-2036. doi: 10.1200/JCO.2016.70.1508. Epub 2017 May 2. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Characterize the adverse events associated with CDX-1127 administration	Analysis of adverse events along with the results of vital sign measurements, physical examinations, and clinical laboratory tests will be used to determine the safety profile of CDX-1127.	Safety follow up is 70 days from last dose.
Secondary	Levels of anti-CD27 antibodies in circulating blood.		Until end of treatment
Secondary	Levels of CDX-1127 in circulating blood.		Until end of treatment
Secondary	Activity Evaluations	Determine the anti-malignant cell activity of CDX-1127 based on change from baseline in tumor measurements every 12 weeks.	Until disease progression
Secondary	Immune system effects (eg: lymphoid cell populations and serum cytokine levels)		Until end of treatment

External Links

•   Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors